Short answer
Beam Therapeutics Inc. (BEAM) filed an 8-K current report with the SEC on March 5, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement). Bio Palette License Agreement terminated March 2, 2026 due to Bio Palette's planned dissolution: no future payments owed by either party.
Beam Therapeutics Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.02 · Termination of a Material Definitive Agreement
- Bio Palette License Agreement terminated March 2, 2026 due to Bio Palette's planned dissolution: no future payments owed by either party
- Continuity secured: Kobe University standby license (signed Feb 9, 2026) activated, preserving BEAM's exclusive base editing patent rights
- Kobe license is exclusive even as to Kobe itself: same scope as original Bio Palette license for human disease treatment globally
- BEAM also loses its granted license to Bio Palette for microbiome field in Asia, though this was a non-core territory for the company
- Net impact: IP position largely preserved via pre-arranged Kobe backstop; dissolution of counterparty poses minimal disruption risk
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Beam Therapeutics Inc. 8-K filings
Get the next BEAM 8-K as it lands
Follow BEAM for push alerts, or ask the research agent what this filing means.